Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIFT I: Viekirax in Japanese Adults with HCV Genotype 1b
NCT02023099Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2013
- Primary completion
- Oct 2014
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 3 trial of paritaprevir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Dec 2013; status: completed.
02
Drugs
paritaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02023099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02023099.